Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127283031 | 12728303 | 1 | I | 20150923 | 20160905 | 20160909 | 20160909 | EXP | CH-SM-2016-06854 | CH-VIIV HEALTHCARE LIMITED-CH2016128909 | VIIV | 53.37 | YR | F | Y | 0.00000 | 20160909 | MD | CH | CH |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127283031 | 12728303 | 1 | SS | ZYPREXA | OLANZAPINE | 1 | Intramuscular | 15 MG, QD | 750 | MG | Y | 0 | 15 | MG | QD | ||||
| 127283031 | 12728303 | 2 | SS | ZYPREXA | OLANZAPINE | 1 | Oral | 15 MG, QD | 750 | MG | Y | 0 | 15 | MG | QD | ||||
| 127283031 | 12728303 | 3 | SS | ZYPREXA | OLANZAPINE | 1 | 10 MG, QD | 750 | MG | Y | 0 | 10 | MG | QD | |||||
| 127283031 | 12728303 | 4 | SS | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Oral | 960 MG, UNK, 3 TIMES/WEEK | Y | 0 | 960 | MG | |||||||
| 127283031 | 12728303 | 5 | PS | TRIUMEQ | ABACAVIR SULFATEDOLUTEGRAVIR SODIUMLAMIVUDINE | 1 | Oral | 1 DF, QD | 205551 | 1 | DF | QD | |||||||
| 127283031 | 12728303 | 6 | SS | Mefenacid | MEFENAMIC ACID | 1 | Oral | 250 MG, TID, FREQUENCY OF USE 2-3 X A MONTH DURING THE HOSPITAL STAY, THEN UNKNOWN | U | 0 | 250 | MG | TID | ||||||
| 127283031 | 12728303 | 7 | SS | DAFALGAN | ACETAMINOPHEN | 1 | Oral | 1 G, TID, MAX 3 TIMES A DAY, FREQUENCY OF USE 1-3 X/WEEK DURING THE HOSPITAL STAY, THEN UNKNOWN | U | 0 | 1 | G | TID | ||||||
| 127283031 | 12728303 | 8 | C | VANNAIR | BUDESONIDEFORMOTEROL FUMARATE DIHYDRATE | 1 | Respiratory (inhalation) | 1 PUFF(S), BID | U | 0 | 1 | DF | BID | ||||||
| 127283031 | 12728303 | 9 | C | FLUIMUCIL | ACETYLCYSTEINE | 1 | Oral | 600 MG, QD | U | 0 | 600 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127283031 | 12728303 | 1 | Schizoaffective disorder |
| 127283031 | 12728303 | 4 | Antibiotic prophylaxis |
| 127283031 | 12728303 | 5 | HIV infection |
| 127283031 | 12728303 | 6 | Product used for unknown indication |
| 127283031 | 12728303 | 7 | Product used for unknown indication |
| 127283031 | 12728303 | 8 | Asthma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127283031 | 12728303 | LT |
| 127283031 | 12728303 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127283031 | 12728303 | Epistaxis | |
| 127283031 | 12728303 | Petechiae | |
| 127283031 | 12728303 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127283031 | 12728303 | 1 | 20150624 | 0 | ||
| 127283031 | 12728303 | 2 | 20150702 | 0 | ||
| 127283031 | 12728303 | 3 | 20150710 | 20160428 | 0 | |
| 127283031 | 12728303 | 4 | 20151223 | 20160428 | 0 | |
| 127283031 | 12728303 | 5 | 201603 | 0 | ||
| 127283031 | 12728303 | 6 | 201504 | 0 | ||
| 127283031 | 12728303 | 7 | 201408 | 0 | ||
| 127283031 | 12728303 | 8 | 201608 | 0 | ||
| 127283031 | 12728303 | 9 | 20151029 | 201608 | 0 |